Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
Key Highlights
- ➤CLN-049 showed anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg
- ➤CLN-049’s double step-up dosing regimen demonstrated a favorable safety profile
- ➤Velinotamig preclinical data showed selective targeting of BCMA-expressing B-lineage cells
- ➤Cullinan will present four posters covering CLN-049 and velinotamig at ASH December 12-15
- ➤CLN-049 combination study advances in newly diagnosed AML with azacitidine and venetoclax
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3 T cell engager, and velinotamig (CLN-803), a BCMAxCD3 T cell engager, will be featured across four poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15 in New Orleans, Louisiana.
Cullinan will present updated data from the CLN-049 Phase 1 dose escalation study in patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The abstract reports the anti-leukemic activity of the selected Phase 2 target doses of 6 µg/kg and 12 µg/kg, and a favorable safety profile for the double step-up dosing regimen. Updated dose escalation results for the selected Phase 2 regimens will be further detailed in the poster presentation.
Get started
Create a free account to read the full story.